Cholangiocarcinoma and liver transplantation: What we know so far?
Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplanta...
Gespeichert in:
| Veröffentlicht in: | World journal of gastrointestinal pathophysiology 2021-09, Vol.12 (5), p.84-105 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105 |
|---|---|
| container_issue | 5 |
| container_start_page | 84 |
| container_title | World journal of gastrointestinal pathophysiology |
| container_volume | 12 |
| creator | Safarpour, Ali Reza Askari, Hassan Ejtehadi, Farshid Azarnezhad, Asaad Raeis-Abdollahi, Ehsan Tajbakhsh, Amir Abazari, Mohammad Foad Tarkesh, Firoozeh Shamsaeefar, Alireza Niknam, Ramin Sivandzadeh, Gholam Reza Lankarani, Kamran Bagheri Ejtehadi, Fardad |
| description | Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA. |
| doi_str_mv | 10.4291/wjgp.v12.i5.84 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8481789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584437592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2124-c094308c71b5c537e5c3048c926329f1018e252a36ccae11794712533c601b823</originalsourceid><addsrcrecordid>eNpVUEtLAzEQDqJYqb16ztFL1zx3Ew-KFl9Q8KJ4DGmabVN3kzXZtvjvTWkRncsMfMP3AuACo4IRia-2q0VXbDApHC8EOwJnBHM05pSi4z_3AIxSWqE8jJclQ6dgQFlZlZjIM3A_WYZG-4ULRkfjfGg11H4OG7exEfZR-9RlvNe9C_4afix1D7cWfvqwhSnAWsfbc3BS6ybZ0WEPwfvjw9vkeTx9fXqZ3E3HhmDCxgZJRpEwFZ5xw2lluaGICSNJSYmsMcLCEk40LY3RFuNKsgqTHMCUCM8EoUNws-ft1rPWzo312V6juuhaHb9V0E79R7xbqkXYKMEEroTMBJcHghi-1jb1qnXJ2Cbns2GdFOGCMVpxudMq9q8mhpSirX9lMFK77tWue5W7V45nAfoDsq92RQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584437592</pqid></control><display><type>article</type><title>Cholangiocarcinoma and liver transplantation: What we know so far?</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Safarpour, Ali Reza ; Askari, Hassan ; Ejtehadi, Farshid ; Azarnezhad, Asaad ; Raeis-Abdollahi, Ehsan ; Tajbakhsh, Amir ; Abazari, Mohammad Foad ; Tarkesh, Firoozeh ; Shamsaeefar, Alireza ; Niknam, Ramin ; Sivandzadeh, Gholam Reza ; Lankarani, Kamran Bagheri ; Ejtehadi, Fardad</creator><creatorcontrib>Safarpour, Ali Reza ; Askari, Hassan ; Ejtehadi, Farshid ; Azarnezhad, Asaad ; Raeis-Abdollahi, Ehsan ; Tajbakhsh, Amir ; Abazari, Mohammad Foad ; Tarkesh, Firoozeh ; Shamsaeefar, Alireza ; Niknam, Ramin ; Sivandzadeh, Gholam Reza ; Lankarani, Kamran Bagheri ; Ejtehadi, Fardad</creatorcontrib><description>Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.</description><identifier>ISSN: 2150-5330</identifier><identifier>EISSN: 2150-5330</identifier><identifier>DOI: 10.4291/wjgp.v12.i5.84</identifier><identifier>PMID: 34676129</identifier><language>eng</language><publisher>Baishideng Publishing Group Inc</publisher><subject>Review</subject><ispartof>World journal of gastrointestinal pathophysiology, 2021-09, Vol.12 (5), p.84-105</ispartof><rights>The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2124-c094308c71b5c537e5c3048c926329f1018e252a36ccae11794712533c601b823</citedby><cites>FETCH-LOGICAL-c2124-c094308c71b5c537e5c3048c926329f1018e252a36ccae11794712533c601b823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481789/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481789/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids></links><search><creatorcontrib>Safarpour, Ali Reza</creatorcontrib><creatorcontrib>Askari, Hassan</creatorcontrib><creatorcontrib>Ejtehadi, Farshid</creatorcontrib><creatorcontrib>Azarnezhad, Asaad</creatorcontrib><creatorcontrib>Raeis-Abdollahi, Ehsan</creatorcontrib><creatorcontrib>Tajbakhsh, Amir</creatorcontrib><creatorcontrib>Abazari, Mohammad Foad</creatorcontrib><creatorcontrib>Tarkesh, Firoozeh</creatorcontrib><creatorcontrib>Shamsaeefar, Alireza</creatorcontrib><creatorcontrib>Niknam, Ramin</creatorcontrib><creatorcontrib>Sivandzadeh, Gholam Reza</creatorcontrib><creatorcontrib>Lankarani, Kamran Bagheri</creatorcontrib><creatorcontrib>Ejtehadi, Fardad</creatorcontrib><title>Cholangiocarcinoma and liver transplantation: What we know so far?</title><title>World journal of gastrointestinal pathophysiology</title><description>Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.</description><subject>Review</subject><issn>2150-5330</issn><issn>2150-5330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVUEtLAzEQDqJYqb16ztFL1zx3Ew-KFl9Q8KJ4DGmabVN3kzXZtvjvTWkRncsMfMP3AuACo4IRia-2q0VXbDApHC8EOwJnBHM05pSi4z_3AIxSWqE8jJclQ6dgQFlZlZjIM3A_WYZG-4ULRkfjfGg11H4OG7exEfZR-9RlvNe9C_4afix1D7cWfvqwhSnAWsfbc3BS6ybZ0WEPwfvjw9vkeTx9fXqZ3E3HhmDCxgZJRpEwFZ5xw2lluaGICSNJSYmsMcLCEk40LY3RFuNKsgqTHMCUCM8EoUNws-ft1rPWzo312V6juuhaHb9V0E79R7xbqkXYKMEEroTMBJcHghi-1jb1qnXJ2Cbns2GdFOGCMVpxudMq9q8mhpSirX9lMFK77tWue5W7V45nAfoDsq92RQ</recordid><startdate>20210922</startdate><enddate>20210922</enddate><creator>Safarpour, Ali Reza</creator><creator>Askari, Hassan</creator><creator>Ejtehadi, Farshid</creator><creator>Azarnezhad, Asaad</creator><creator>Raeis-Abdollahi, Ehsan</creator><creator>Tajbakhsh, Amir</creator><creator>Abazari, Mohammad Foad</creator><creator>Tarkesh, Firoozeh</creator><creator>Shamsaeefar, Alireza</creator><creator>Niknam, Ramin</creator><creator>Sivandzadeh, Gholam Reza</creator><creator>Lankarani, Kamran Bagheri</creator><creator>Ejtehadi, Fardad</creator><general>Baishideng Publishing Group Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210922</creationdate><title>Cholangiocarcinoma and liver transplantation: What we know so far?</title><author>Safarpour, Ali Reza ; Askari, Hassan ; Ejtehadi, Farshid ; Azarnezhad, Asaad ; Raeis-Abdollahi, Ehsan ; Tajbakhsh, Amir ; Abazari, Mohammad Foad ; Tarkesh, Firoozeh ; Shamsaeefar, Alireza ; Niknam, Ramin ; Sivandzadeh, Gholam Reza ; Lankarani, Kamran Bagheri ; Ejtehadi, Fardad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2124-c094308c71b5c537e5c3048c926329f1018e252a36ccae11794712533c601b823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Safarpour, Ali Reza</creatorcontrib><creatorcontrib>Askari, Hassan</creatorcontrib><creatorcontrib>Ejtehadi, Farshid</creatorcontrib><creatorcontrib>Azarnezhad, Asaad</creatorcontrib><creatorcontrib>Raeis-Abdollahi, Ehsan</creatorcontrib><creatorcontrib>Tajbakhsh, Amir</creatorcontrib><creatorcontrib>Abazari, Mohammad Foad</creatorcontrib><creatorcontrib>Tarkesh, Firoozeh</creatorcontrib><creatorcontrib>Shamsaeefar, Alireza</creatorcontrib><creatorcontrib>Niknam, Ramin</creatorcontrib><creatorcontrib>Sivandzadeh, Gholam Reza</creatorcontrib><creatorcontrib>Lankarani, Kamran Bagheri</creatorcontrib><creatorcontrib>Ejtehadi, Fardad</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastrointestinal pathophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Safarpour, Ali Reza</au><au>Askari, Hassan</au><au>Ejtehadi, Farshid</au><au>Azarnezhad, Asaad</au><au>Raeis-Abdollahi, Ehsan</au><au>Tajbakhsh, Amir</au><au>Abazari, Mohammad Foad</au><au>Tarkesh, Firoozeh</au><au>Shamsaeefar, Alireza</au><au>Niknam, Ramin</au><au>Sivandzadeh, Gholam Reza</au><au>Lankarani, Kamran Bagheri</au><au>Ejtehadi, Fardad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cholangiocarcinoma and liver transplantation: What we know so far?</atitle><jtitle>World journal of gastrointestinal pathophysiology</jtitle><date>2021-09-22</date><risdate>2021</risdate><volume>12</volume><issue>5</issue><spage>84</spage><epage>105</epage><pages>84-105</pages><issn>2150-5330</issn><eissn>2150-5330</eissn><abstract>Cholangiocarcinoma (CCA) is a type of cancer with increasing prevalence around the world that originates from cholangiocytes, the epithelial cells of the bile duct. The tumor begins insidiously and is distinguished by high grade neoplasm, poor outcome, and high risk for recurrence. Liver transplantation has become broadly accepted as a treatment option for CCA. Liver transplantation is expected to play a crucial role as palliative and curative therapy for unresectable hilar CCA and intrahepatic CCA. The purpose of this study was to determine which cases with CCA should be subjected to liver transplantation instead of resection, although reported post-transplant recurrence rate averages approximately 20%. This review also aims to highlight the molecular current frontiers of CCA and directions of liver transplantation for CCA.</abstract><pub>Baishideng Publishing Group Inc</pub><pmid>34676129</pmid><doi>10.4291/wjgp.v12.i5.84</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2150-5330 |
| ispartof | World journal of gastrointestinal pathophysiology, 2021-09, Vol.12 (5), p.84-105 |
| issn | 2150-5330 2150-5330 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8481789 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Review |
| title | Cholangiocarcinoma and liver transplantation: What we know so far? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T04%3A16%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cholangiocarcinoma%20and%20liver%20transplantation:%20What%20we%20know%20so%20far?&rft.jtitle=World%20journal%20of%20gastrointestinal%20pathophysiology&rft.au=Safarpour,%20Ali%20Reza&rft.date=2021-09-22&rft.volume=12&rft.issue=5&rft.spage=84&rft.epage=105&rft.pages=84-105&rft.issn=2150-5330&rft.eissn=2150-5330&rft_id=info:doi/10.4291/wjgp.v12.i5.84&rft_dat=%3Cproquest_pubme%3E2584437592%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584437592&rft_id=info:pmid/34676129&rfr_iscdi=true |